Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non-small cell lung cancer (NSCLC). In this educational program, these experts explore the critical differences between c-Met protein overexpression and MET exon 14 skipping mutations in NSCLC. Faculty delve into the latest therapeutic advancements, including antibody-drug conjugates targeting c-Met and tyrosine kinase inhibitors for MET exon 14 mutations, emphasizing clinical trial data and real-world applications.
This educational activity is an archive of the live presentation held on July 24, 2026.
Target Audience
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess molecular testing strategies for identifying categories of MET alterations in patients with NSCLC
- Apply FDA-approved and investigational c-MET–directed therapies based on the type of MET alteration in patients with advanced NSCLC
- Evaluate emerging clinical evidence for next-generation c-MET–targeting agents and combination strategies in MET-dysregulated NSCLC
- Develop evidence-based approaches to identify and manage adverse events associated with c-MET–directed therapies, including those specific to antibody-drug conjugates
Jonathan Goldman, MD
Professor of Medicine, Division of Hematology/Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Early Drug Development
University of California, Los Angeles
Santa Monica, CA
Sanja Dacic, MD, PhD
Professor of Pathology
Vice Chair and Director of Anatomic Pathology
Director, Thoracic Pathology
Department of Pathology
Yale School of Medicine
New Haven, CT
Deborah Doroshow, MD, PhD
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Anne S. Tsao, MD, MBA
Vice President, Academic Affairs
Professor, Thoracic/Head and Neck Medical Oncology
Director, Mesothelioma Program
The University of Texas MD Anderson Cancer Center
Houston, TX
Faculty disclosures are available in the document linked here.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.